SCHEMBL7983980

SCHEMBL7983980

CC(C)(C)OC(=O)N1CCC(CNC(=O)C2CC3C=Cc4cccc(c43)S2)CC1

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
PKM P14618 1/20 0.50
FPR3 P25089 1/20 0.44
FPR2 P25090 1/20 0.44
TGFBR1 P36897 11/20 0.41
STS P08842 2/20 0.40
KMT2A Q03164 1/20 0.39
TP53 P04637 1/20 0.39
ACKR3 P25106 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8502163 0.73 KDM4E (0.49) KDM4EPKMFPR3FPR2TGFBR1
SCHEMBL21551436 0.70 KDM4E (0.63) KDM4EPKMFPR3FPR2STS
SCHEMBL7983977 0.69 KDM4E (0.50) KDM4EPKMFPR3FPR2TGFBR1
SCHEMBL13947430 0.69 KDM4E (0.80) KDM4EPKMKMT2ATP53
SCHEMBL6148210 0.68 KDM4E (0.71) KDM4EPKMTGFBR1STSACKR3
SCHEMBL13812320 0.68 KDM4E (0.60) KDM4EPKMFPR3FPR2STS
SCHEMBL31402457 0.68 KDM4E (0.60) KDM4EPKMFPR3FPR2STS
SCHEMBL26131403 0.68 KDM4E (1.00) KDM4EPKMTGFBR1STSKMT2A
SCHEMBL21551407 0.68 KDM4E (0.63) KDM4EPKMFPR3FPR2TGFBR1
SCHEMBL27604112 0.67 KDM4E (0.54) KDM4EPKMTGFBR1STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6235731-B1 REDUCING BLOOD LIPIDS, SUGARS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed
EP-0915888-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS Takeda Chemical Industries, Ltd. (JP) 1999-05-19 EP disclosed
WO-1997040051-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-30 WO disclosed